Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment

Curr Rheumatol Rep. 2017 Aug;19(8):52. doi: 10.1007/s11926-017-0676-2.

Authors

Virginie Dufrost¹, Jessie Risse^{1

2}, Denis Wahl^{1

2}, Stéphane Zuily^{3

4}

Affiliations

¹ Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France.
² Inserm UMR_S 1116 at Lorraine University, Nancy, France.
³ Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France. s.zuily@chru-nancy.fr.
⁴ Inserm UMR_S 1116 at Lorraine University, Nancy, France. s.zuily@chru-nancy.fr.

PMID: 28741234
DOI: 10.1007/s11926-017-0676-2

No abstract available

Keywords: Antiphospholipid antibodies; Antiphospholipid syndrome; Direct oral anticoagulants; Rivaroxaban; Thrombosis; Triple positivity.

Publication types

Letter
Comment

MeSH terms

Anticoagulants
Antiphospholipid Syndrome*
Humans
Warfarin*

Substances

Anticoagulants
Warfarin